Health Economics studies

Our health economics research focuses on improving the value of medical care. We analyze usage patterns of health care services and medications, and the resulting economic, clinical, and patient-reported outcomes; evaluate intervention and treatments aimed at improving patient care in real-world clinical settings, and also assess comparative effectiveness, medication adherence and persistence, and quality of life for patients using alternative treatment choices.

Economic, Epidemiologic and Clinical Burden Associated with Neutropenia and Febrile Neutropenia in Three Cancers

The primary objective of this study is to estimate the resource utilization and direct medical expenditure associated with neutropenia and febrile neutropenia, in Non-Hodgkin’s Lymphoma, Breast cancer and Lung cancer patients. The secondary objective is to determine the trend of incidence of neutropenia with and without fever in Non-Hodgkin’s Lymphoma, Breast cancer and Lung cancer. The study will also describe management patterns and evaluate trend of management patterns for febrile neutropenia. Lastly, we will also estimate the febrile neutropenia specific mortality rate in hospitalized patients by cancer type.

Principal Investigator:

Aniket A. Kawatkar, PhD, MS

Funding Source:

Amgen, Inc.

Funding Years:

2011 - 2015

Medical Expenditure Panel Survey (MEPS)

The aim of this study is to verify the cost of care for persons with multiple sclerosis.

Principal Investigator:

Annette M. Langer-Gould, MD, PhD, MS

Funding Source:

National Multiple Sclerosis Society (NMSS)

Funding Years:

2013

Patterns and Predictors of Transitions in Adult Attention-Deficit Hyperactivity Disorder

This study will estimate the epidemiologic and economic outcomes associated with the adult attention deficit hyperactivity disorder (ADHD). We also assess characteristics, predictors, and time frame for patients who transition to more complex ADHD within the inception cohort and generate prediction models for transition. The study also examines treatment patterns, medication adherence and healthcare utilization patterns of the inception cohort.

Principal Investigator:

Aniket A. Kawatkar, PhD, MS

Funding Source:

Shire Pharmaceuticals

Funding Years:

2009 - 2012

Total Direct Medical Expenditure Associated with Transition to Diverticulitis

This study will estimate the economic, clinical and epidemiologic outcomes associated with the transition from diverticulosis to diverticulitis. We further assess these outcomes associated with recurrence of diverticulitis and also investigate mortality risk due to the disease and during surgical treatments. The study also examines the socio-demographic and other factors associated with diverticulitis and its recurrence; barrier’s to surgical treatment alternatives and associated utilization; other treatment options for this disease.

Principal Investigator:

Aniket A. Kawatkar, PhD, MS

Funding Source:

Shire Pharmaceuticals

Funding Years:

2009 - 2015